ArticleEuropean journal of medical research2025
Effects of beinaglutide on visceral fat area and gut microbiota in obesity.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Article
- Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs).Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe gut microbiota plays a substantial role in obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can affect body weight, insulin resistance, and lipid metabolism via combined hypothalamic feeding centre and gastrointestinal tract activity. It also affects the intestinal flora of patients with obesity. We investigated changes in visceral fat and gut microbiota of patients with obesity treated with beinaglutide.
methodsThirty-three patients from our hospital with obesity treated with beinaglutide and 20 sex- and age-matched healthy controls were included based on the inclusion and exclusion criteria. Glycolipid metabolism indices, inflammation indices, and hepatic and renal functions were assessed at treatment initiation and 4 and 12 weeks after treatment. Body weight, waist circumference, blood pressure, and body composition (visceral fat area, body fat, body fat percentage, skeletal muscle, and basal metabolic rate) were measured. The Homeostatic Model Assessment of Insulin Resistance index was calculated. Fecal samples were collected from 12 cases. Effects on intestinal flora were assessed by sequencing the V3-V4 region of the 16S rRNA gene.
resultsBeinaglutide significantly reduced visceral fat area, improved glycolipid metabolism, and decreased total cholesterol, low-density lipoprotein cholesterol, blood glucose, and C-reactive protein levels. It also considerably restored the α-diversity of intestinal flora, with decreased in relative abundances of Prevotella, Lachnospira and Dialister at the genus level and increased in the relative abundance of Blautia A and Gemmiger A.
conclusionsOur findings provide insights into the mechanisms by which beinaglutide aids weight loss, particularly via modulating the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.